A retrospective observational study of elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis with advanced lung disease and no F508del CFTR variant
Latest Information Update: 21 Feb 2023
At a glance
- Drugs Elexacaftor/ivacaftor/tezacaftor (Primary)
- Indications Cystic fibrosis
- Focus Therapeutic Use
Most Recent Events
- 21 Feb 2023 New trial record
- 16 Feb 2023 Results published in the European Respiratory Journal